OBJECTIVE： To investigate the effects of tiotropium bromide combined with olodaterol on senum inflammatory factor levels and pulmonary function in patients with chronic obstructive pulmonary disease （COPD） of stable period. METHODS： From May 2015 to Oct. 2016， 135 patients with COPD stable period in our hospital were selected as the research objects， and divided into 3 groups according to random number table， with 45 cases in each group. All groups were given conventional treatment and aerosol inhalation of salbutamol sulfate atomized inhalation solution. On this basis， group A was given aerosol inhalation of Tiotropium bromide powder for inhalation， once a night before bedtime， 18 μg per time. Group B was given inhalation of Olodaterol spray， qd， 5 μg per time. Group C was given  Tiotropium bromide powder for inhalation and Olodaterol spray with same usage and dosage as group A and B. All 3 groups were treatment for 12 months. The changes of serum inflammatory factors （TNF-α， IL-8 and IL-10） and pulmonary function （FEV1， FVC， PEF） were compared among 3 groups before treatment and 6， 12 months after treatment. After 12-month follow-up， the qualities of life in 3 groups were evaluated by CAT scale. The occurrence of ADR was recorded in 3 groups. RESULTS： Before treatment， there was no statistical significance in above indexes among 3 groups （P＞0.05）. After 6， 12 months of treatment， the levels of TNF-α and IL-8 in 3 groups were significantly lower than before treatment， while IL-10 level， FEV1， FVC and PEF were significantly higher than before treatment； above indexes of group C were significantly better than those of group A and B， with statistical significance （P＜0.05）. After 12 months of treatment， CAT scores of 3 groups were significantly lower than before treatment， and those of group C were significantly lower than group A and B， with statistical significance （P＜0.05）. There was no statistical significance in the incidence of ADR among 3 groups （P＞0.05）， without severe ADR. CONCLUSIONS： Tiotropium bromide combined with olodaterol shows definite efficacy for COPD stable period， not only can effectively reduce the level of inflammatory factors and relieve airway inflammatory response， but also can significantly improve the patient’s lung function and quality of life， without increasing ADR.